Cited by 256Pulmonary Hypertension Research and TreatmentsVascular Anomalies and TreatmentsVenous Thromboembolism Diagnosis and Management

The DOI matches its Crossref record; 102 of the 104 references it cites were found in a registry or an index.

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Open access

Taichman, Darren B., Ornelas, Joe, Chung, Lorinda, Klinger, James R., Lewis, Sandra, Mandel, Jess, Palevsky, Harold I., Rich, Stuart, Sood, Namita, Rosenzweig, Erika B., Trow, Terence K., Yung, Rex, Elliott, C. Gregory, Badesch, David B.·2014·Chest

DOI 10.1378/chest.14-0793PMC PMC4137591

Open this paper in CoChat — free account Open PDF

Abstract

Objective Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH) are ideally guided by high-level evidence. The objective of this guideline is to provide clinicians advice regarding pharmacologic therapy for adult patients with PAH as informed by available evidence.Methods This guideline was based on systematic reviews of English language evidence published between 1990 and November 2013, identified using the MEDLINE and Cochrane Library databases. The strength of available evidence was graded using the Grades of Recommendations, Assessment, Development, and Evaluation methodology. Guideline recommendations, or consensus statements when available evidence was insufficient to support recommendations, were developed using a modified Delphi technique to achieve consensus.Results Available evidence is limited in its ability to support high-level recommendations. Therefore, we drafted consensus statements to address many clinical questions regarding pharmacotherapy for patients with PAH. A total of 79 recommendations or consensus statements were adopted and graded.Conclusions Clinical decisions regarding pharmacotherapy for PAH should be guided by high-level recommendations when sufficient evidence is available. Absent higher level evidence, consensus statements based upon available information must be used. Further studies are needed to address the gaps in available knowledge regarding optimal pharmacotherapy for PAH.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1378/chest.14-0793

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
The “Golden Age” of Probiotics: A Systematic Review and Meta-Analysis of Randomized and Observational Studies in Preterm Infants
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,586
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness
Rosa, S. D., Samoni, S., Villa, G., & Ronco, C. (2017) · Blood Purification · doi:10.1159/000452650 · Cited by 5,040
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Hoeper, M. M., Humbert, M. J. C., Torbicki, A., Vachiéry, J., Barberà, J. A., Beghetti, M., Corris, P. A., Gaine, S., Gibbs, J. S. R., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp297 · Cited by 3,853
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., KEOGH, A. M., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,718
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. Μ., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,688
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D. B., Fleming, T. R., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,466
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,359

Flagged first, then by citations

Show all 104 references

2 of the 104 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 255

Perioperative Management of Patients With Pulmonary Hypertension for Non-Cardiac Surgery
Yang, E. I. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-014-0490-z · Cited by 18
Bioactive Compounds From Coptidis Rhizoma Alleviate Pulmonary Arterial Hypertension by Inhibiting Pulmonary Artery Smooth Muscle Cells' Proliferation and Migration
Luo, S., Kan, J., Zhang, J., Ye, P., Wang, D., Jiang, X., Li, M., Zhu, L., & Gu, Y. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001068 · Cited by 17
Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials
Gao, X., Zhang, J., Jiang, X., Ge, Z., Wang, Z., Li, B., Mao, W., & Chen, S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s133288 · Cited by 17
The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges
Swisher, J. W., & Weaver, E. (2023) · Vascular Health and Risk Management · doi:10.2147/vhrm.s321025 · Cited by 17
A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy
Ataya, A., Cope, J. M., & Alnuaimat, H. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5120114 · Cited by 16
Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman
Wollein, U., Schech, B., Hardt, J., & Schramek, N. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.12.006 · Cited by 16
Potential new drug treatments for congestive heart failure
Tran, H. A., Lin, F., & Greenberg, B. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1181749 · Cited by 16
Formulation and evaluation of inhaled Sildenafil-loaded PLGA microparticles for treatment of pulmonary arterial hypertension (PAH): A novel high drug loaded formulation and scalable process via hot melt extrusion technology (Part Ⅰ)
Almutairi, M., Hefnawy, A., Almotairy, A., Alobaida, A., Alyahya, M., Althobaiti, A. A., Youssef, A. A. A., Elkanayati, R. M., Ashour, E. A., Smyth, H. D. C., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124044 · Cited by 15
Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Hill, N. S., Rahaghi, F., Sood, N., Frey, R., & Ghofrani, H. A. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.05.005 · Cited by 15
Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
Davey, R., Benza, R. L., Murali, S., & Raina, A. (2017) · Pulmonary Circulation · doi:10.1177/2045893217708566 · Cited by 15
The metabolism and drug–drug interaction potential of the selective prostacyclin receptor agonist selexipag
Gnerre, C., Segrestaa, J., Seeland, S., Äänismaa, P., Pfeifer, T., Delahaye, S., de Kanter, R., Ichikawa, T., Yamada, T., & Treiber, A. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1357088 · Cited by 15
Update on pharmacotherapy for pulmonary hypertension
Prior, D., Adams, H. S. L., & Williams, T. J. (2016) · The Medical Journal of Australia · doi:10.5694/mja16.00468 · Cited by 14
Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension
Thurber, K. M., Williams, B. M., Bates, R. E., & Frantz, R. P. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1951 · Cited by 14
Pulmonary Arterial Hypertension in Indonesia: Current Status and Local Application of International Guidelines
Dinarti, L. K., Anggrahini, D. W., Lilyasari, O., Siswanto, B. B., & Hartopo, A. B. (2021) · Global Heart · doi:10.5334/gh.944 · Cited by 14
Severe pulmonary arterial hypertension: stratification of medical therapies, mechanical support, and lung transplantation
Bartolome, S., & Torres, F. (2016) · Heart Failure Reviews · doi:10.1007/s10741-016-9562-7 · Cited by 14
Monitoring and Diagnostic Approaches for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis
Valenzuela, A., Nandagopal, S., Steen, V. D., & Chung, L. S. (2015) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.04.009 · Cited by 14
Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review
Gu, Z., Zhang, C., Wei, A., Cui, M., Pu, J., Lin, H., & Liu, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-16349-7 · Cited by 13
Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition
Mensah, K. A., Yadav, R., Trow, T. K., Brunet, C. M., & Fares, W. H. (2015) · Case Reports in Medicine · doi:10.1155/2015/328435 · Cited by 13
A review of therapeutic agents for the management of pulmonary arterial hypertension
Hahn, S. S., Makaryus, M. R., Talwar, A., Narasimhan, M., & Zaidi, G. Z. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816665289 · Cited by 13
Existing Drugs and Agents Under Investigation for Pulmonary Arterial Hypertension
Sharma, M., Pinnamaneni, S., Aronow, W. S., Jozwik, B., & Frishman, W. H. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000035 · Cited by 12
Practical management of riociguat in patients with pulmonary arterial hypertension
Halank, M., Tausche, K., Grünig, E., Ewert, R., & Preston, I. R. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619868938 · Cited by 13
Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
Sulica, R., Fenton, R., & Cefali, F. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0046-y · Cited by 12
Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV‐1‐infected adults
DeJesus, E., Saleh, S., Cheng, S., van der Mey, D., Becker, C., Frey, R., Unger, S., & Mueck, W. (2019) · Pulmonary Circulation · doi:10.1177/2045894019848644 · Cited by 12
A novel approach to perioperative risk assessment for patients with pulmonary hypertension
Hassan, H. J., Housten, T., Balasubramanian, A., Simpson, C. E., Damico, R. L., Mathai, S. C., Hassoun, P. M., Steppan, J., Leary, P. J., & Kolb, T. M. (2021) · ERJ Open Research · doi:10.1183/23120541.00257-2021 · Cited by 12
Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study
Yuan, W., Liu, M., Yang, D., Shi, Y., Wang, Z., Cao, X., Liang, J., Geng, L., Zhang, H., Feng, X., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04237-1 · Cited by 11
Parenteral Prostanoid Use at a Tertiary Referral Center
Hay, B. R., Pugh, M. E., Robbins, I. M., & Hemnes, A. R. (2015) · CHEST Journal · doi:10.1378/chest.15-1051 · Cited by 11
Speckle Tracking Echocardiography to Evaluate for Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease
Rice, J. L., Stream, A. R., Fox, D. L., Geraci, M. W., Vandivier, R. W., Dorosz, J. L., & Bull, T. (2016) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2015.1134468 · Cited by 11
Riociguat and sildenafil for pulmonary hypertension: similarity and difference
Шмальц, А. А., & Gorbachevskiy, S. V. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-1-85-91 · Cited by 11
Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
Coons, J. C., & Miller, T. J. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618766490 · Cited by 11
Phosphodiesterase-5 (PDE-5) Inhibitors as Emergent Environmental Contaminants: Advanced Remediation and Analytical Methods
Bianco, G. L., Foti, L., Pascale, R., Lelario, F., Coviello, D., Brienza, M., Bufo, S. A., & Scrano, L. (2021) · Water · doi:10.3390/w13202859 · Cited by 10
PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC CONNECTIVE TISSUE DISEASES: THE CURRENT STATE OF THE PROBLEM
Volkov, A. V., & Martynyuk, T. V. (2018) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2018-474-485 · Cited by 10
Integrated Transitions of Care for Patients With Rare Pulmonary Diseases
Moreo, K., Lattimer, C., Lett, J. E., Heggen, C. L., & Simone, L. (2017) · Professional Case Management · doi:10.1097/ncm.0000000000000198 · Cited by 11
Case report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat
Poch, D. S. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0229-x · Cited by 9
Development of macitentan for the treatment of pulmonary arterial hypertension
Selej, M., Romero, A., Channick, R. N., & Clozel, M. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12856 · Cited by 9
sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension
Benza, R. L., Mathai, S. C., & Nathan, S. D. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.11.010 · Cited by 10
Chronic Right Heart Failure
Chizinga, M., & Fares, W. H. (2018) · Heart Failure Clinics · doi:10.1016/j.hfc.2018.03.007 · Cited by 9
Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
Tynan, T., Hird, K., Hannon, T., & Gabbay, E. (2019) · Journal of International Medical Research · doi:10.1177/0300060519840130 · Cited by 9
Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials
Tan, Z. W., Wu, P., Zhu, T., Su, W., & Fang, Z. (2022) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2022.102144 · Cited by 9
Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat
Martynyuk, T. V., Shmalts, A. A., Gorbachevsky, S. V., & Chazova, I. E. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.09.201014 · Cited by 9
Pulmonary Hypertension Complicating Connective Tissue Disease
Belperio, J. A., Saggar, R., Fishbein, M. C., Saggar, R., & Lynch, J. P. (2013) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0033-1356547 · Cited by 8
The Pulmonary Hypertension Consult
Fritz, J. S., & Smith, K. A. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.05.010 · Cited by 8
Inhaled Iloprost for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) During Pregnancy: A Case Report
Horng, M., Mohammad, I., Smith, Z., Awdish, R., & Cajigas, H. R. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1793 · Cited by 8
Dose, dosage regimen, and dose adjustment in organ failure
Choudhary, D., Goykar, H., Kalyane, D., Desai, N., & Tekade, R. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814425-1.00004-8 · Cited by 8
Adaptation and Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for Use in Spain
Aguirre‐Camacho, A., Stepanous, J., Blanco‐Donoso, L. M., Jiménez, B. M., Wilburn, J. N., González-Saiz, L., & McKenna, S. P. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.11.007 · Cited by 7
Severe Pulmonary Hypertension as Initial Presentation of SLE: A Case Report and Literature Review
Kiani, R. N., Siddiqui, M. D., & Tantoush, H. (2020) · Case Reports in Rheumatology · doi:10.1155/2020/6014572 · Cited by 7
PH Professional Network: The Burden of Prior Authorization for Pulmonary Hypertension Medications: A Practical Guide for Managing the Process
Housten, T., & Brown, A. M. (2018) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-17.3.126 · Cited by 7
Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis
Petrovič, M., & Locatelli, I. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0037 · Cited by 7
Implantable system for treprostinil: a real‐world patient experience study
Shapiro, S., Bourge, R. C., Pozella, P., Harris, D. F., Borg, E., & Nelsen, A. C. (2020) · Pulmonary Circulation · doi:10.1177/2045894020907881 · Cited by 7
Anesthesia and Pulmonary Hypertension: A Narrative Review
Çekmen, N., & Gökdemir, B. N. (2023) · Heart and Mind · doi:10.4103/hm.hm_41_22 · Cited by 6
Current and future direction in the management of scleroderma
Brady, S. M., Shapiro, L. S., & Mousa, S. A. (2016) · Archives of Dermatological Research · doi:10.1007/s00403-016-1647-6 · Cited by 6
New insights into the recognition, classification and management of systemic sclerosis-associated pulmonary hypertension
Mullin, C. J., & Mathai, S. C. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000440 · Cited by 6
Is it possible to apply the treat-to-target strategy in primary Sjögren’s syndrome-associated pulmonary arterial hypertension?
Liu, Z., Wang, J., Lai, J., Wang, Q., Zhao, J., Huang, C. L., Yang, X., Qian, J., Wang, H., Guo, X., et al. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4184-1 · Cited by 6
Mapping the evolution of inhaled drug delivery research: Trends, collaborations, and emerging frontiers
Li, X., Su, Z., Wang, C., Wu, W., Zhang, Y., & Wang, C. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103864 · Cited by 7
Adaptación y validación del cuestionario Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) para uso en España
Aguirre‐Camacho, A., Stepanous, J., Blanco‐Donoso, L. M., Jiménez, B. M., Wilburn, J. N., González-Saiz, L., & McKenna, S. P. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.11.006 · Cited by 6
Cardiac Physiology and Pharmacology
Schure, A. Y., & DiNardo, J. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-42974-0.00018-5 · Cited by 5
Macitentan: An overview of its degradation products, process-related impurities, and in silico toxicity.
Pinto, E. C., de Souza, L. G., Velozo, C. T., Viana, G. M., Cabral, L. M., & de Sousa, V. P. (2022) · Computational Toxicology · doi:10.1016/j.comtox.2022.100255 · Cited by 5
Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
Kimmig, L. M., Liao, C., & Bag, R. (2020) · Lung · doi:10.1007/s00408-019-00306-4 · Cited by 5
Lung
Magalhães, G. S., Campagnole‐Santos, M. J., & Rodrigues‐Machado, M. D. G. (2019) · Springer eBooks · doi:10.1007/978-3-030-22696-1_9 · Cited by 5
Pulmonary Arterial Hypertension Treatment Guidelines
Hemnes, A. R. (2014) · CHEST Journal · doi:10.1378/chest.14-1440 · Cited by 5
Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model
Englert, L., Stadlbauer, C., Spaeth, M., Hofmann, H., Schneider, C. P., Hatz, R. A., Preißler, G., Michel, S. G., Golovchenko, S., Ried, M., et al. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101985 · Cited by 4
OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS
Martynyuk, T. V., Наконечников, С. Н., & Chazova, I. Y. (2017) · Eurasian heart journal · doi:10.38109/2225-1685-2017-2-20-27 · Cited by 4
Prevalence of Sodium and Fluid Restriction Recommendations for Patients with Pulmonary Hypertension
Zeiger, T. K., Cobo, G., Dillingham, C., & Burger, C. (2015) · Healthcare · doi:10.3390/healthcare3030630 · Cited by 4
New Pharmacotherapies for Pulmonary Hypertension: Where Do They Fit in?
Wolfson, A., Steiger, N. A., & Gomberg‐Maitland, M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0496-y · Cited by 4
Self-reported physician practices in pulmonary arterial hypertension: Diagnosis, assessment, and referral
Polanco-Briceno, S., Glass, D., & Cazé, A. (2015) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2015.12.006 · Cited by 4
Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension
Baker, W. L., Darsaklis, K., Singhvi, A., & Salerno, E. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017697424 · Cited by 4
ANTIBIOGRAM STUDY AND ANTIBIOTIC USE EVALUATION USING GYSSEN METHOD IN PATIENTS WITH DIABETIC FOOT
Fadlilah, U., Hasmono, D., Wibisono, Y. A., & Melinda, M. (2017) · Folia Medica Indonesiana · doi:10.20473/fmi.v52i3.5452 · Cited by 4
The burden of at-home preparation of lyophilized parenteral medications: an analysis of contributing factors and implications for chronic disease patients and caregivers
Franzese, C., Thomas, C., Rinaldi, A., Constable, K., Nakamura, K., Kalbermatten, A., & Coyne, M. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1569626 · Cited by 4
miR-29b in regulating blood pressure and cardiac function in the rat model of hypertension
Han, X., Wang, C., Li, Y., Jin, Z., Zhang, B., & Yang, D. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7335 · Cited by 4
A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension
Petrovič, M., & Locatelli, I. (2019) · Annals of Pharmacotherapy · doi:10.1177/1060028019888760 · Cited by 4
Spread the Word About CHEST in 2015
Irwin, R. S., Welch, S. J., Rice, J., & French, C. T. (2015) · CHEST Journal · doi:10.1378/chest.14-2798 · Cited by 4
Selection of Infusion Prostacyclin Therapy in Pulmonary Arterial Hypertension: Not Just a Last Resort
Schilz, R. J., & Park, M. (2017) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-16.1.14 · Cited by 3
Circulating Biomarkers in Pulmonary Arterial Hypertension
Al‐Naamani, N., Trammell, A. W., & Safdar, Z. (2015) · Advances in Pulmonary Hypertension · doi:10.21693/1933-088x-14.1.21 · Cited by 3
Pulmonale Hypertonie: anästhesiologisches Management
Hoetzel, A., & Loop, T. (2019) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-0668-4653 · Cited by 3
Therapeutic Use of an Inhaled Drug Delivery in Pulmonary Hypertension: A Review
Kumbhare, U., Yelne, P., & Tekale, S. (2022) · Cureus · doi:10.7759/cureus.30134 · Cited by 3
Pulmonary manifestations of systemic sclerosis
Sarkar, S. (2022) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_20_22 · Cited by 3
Global research trends in the medical therapy of pulmonary arterial hypertension 2000–2014
Schreiber, C., Edlinger, C. R., Eder, S., Ausserwinkler, M., Wernly, B., Pretsch, I., Jung, C., Hoppe, U. C., & Lichtenauer, M. (2016) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2016.05.004 · Cited by 3
Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model
Hoenicka, M., Golovchenko, S., Englert, L., Spaeth, M., Shoshiashvili, L., Großer, C., Hofmann, H., & Ried, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06868-y · Cited by 3
Perioperative anesthetic considerations in patients with pulmonary hypertension undergoing non-cardiac and non-obstetric surgeries
Seo, J. S., So, K. Y., & Kim, S. H. (2019) · Medical Biological Science and Engineering · doi:10.30579/mbse.2019.2.2.31 · Cited by 3
Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension
Wang, Y., Hu, F., Mu, X., Wu, F., Yang, D., Zheng, G., Sun, X., Gong, K., & Zhang, Z. (2016) · Biorheology · doi:10.3233/bir-15062 · Cited by 3
Nitrogen oxide biochemical pathway in pulmonary arterial hypertension therapy and REPLACE trial results
Shmalts, A. A., & Gorbachevsky, S. V. (2018) · Systemic Hypertension · doi:10.26442/2075-082x_2018.2.72-76 · Cited by 4
Management of adult patients with PAH in Spain: current practice, resources, and needs (AIRE17 Study)
Segovia, J., de Miguel‐Díez, J., Gómez, L., & Cevey, M. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2020.03.006 · Cited by 3
Differentiating pulmonary hypertension associated with protein kinase inhibitors
Jacobs, J. A., Jahangir, E., & Ryan, J. J. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12075 · Cited by 3
A systematic review as a method of gathering scientific evidence into clinical guidelines: CHEST-2019 guideline for the therapy pulmonary arterial hypertension in adults
Shmalts, A. A., & Gorbachevsky, S. V. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.12.000468 · Cited by 3
Real-world use of initial combination treatment in the management of pulmonary arterial hypertension
Sahay, S., Sisk, M., Nelsen, A. C., Wu, B., & Ryan, J. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251390070 · Cited by 2
Early echocardiographic evaluation of right ventricular load adaptability after sequential combination treatment in pulmonary arterial hypertension
Sancar, K. M., Yıldız, M., Kahraman, S., Uygur, B., Bulut, U., Tekin, M., Güler, A., Serbest, N. G., Karakurt, S. T., Yıldız, B. Ş., et al. (2022) · Herz · doi:10.1007/s00059-022-05139-1 · Cited by 2
Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)
Robbins, E. W., Bradley, K., Badesch, D. B., Burger, C. D., Chybowski, A., Marco, T. D., Hemnes, A. R., Lammi, M. R., Mathai, S. C., Melendres-Groves, L. D., et al. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1083oc · Cited by 2
Endothelin Receptor Antagonists
Rodriguez‐Lopez, J., & Channick, R. N. (2015) · Respiratory medicine · doi:10.1007/978-1-4939-2636-7_14 · Cited by 2
Lungenerkrankungen in der Schwangerschaft
Buck, C., Dellas, C., & Ibishi, S. (2015) · Der Gynäkologe · doi:10.1007/s00129-014-3413-1 · Cited by 2
Riociguat in PAH and CTEPH: Strategies for Patient Management
Germani, J., Kingman, M. S., Kitterman, N., Stewart, T., Wilson, M. A., & Zupancic, D. (2017) · Pulmonary Therapy · doi:10.1007/s41030-017-0029-3 · Cited by 2
Impact of Pulmonary Capillary Wedge Pressure on Long-Term Mortality in Patients With Pulmonary Arterial Hypertension Treated With Parenteral Trepostinil
Patel, J., Rao, Y., & Strachan, P. M. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2017.02.015 · Cited by 2
Human factors and usability engineering in the development of SMT-101 for the treatment of pulmonary arterial hypertension
Noymer, P. D., Shaked, A., & Newell, K. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1425390 · Cited by 2
Pulmonary manifestations of systemic lupus erythematosus
Rodriguez, J. V., Doyle, T. J., & Dellaripa, P. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820583-9.00037-3 · Cited by 2
Pulmonary Hypertension
Friedewald, V. E. (2016) · Springer eBooks · doi:10.1007/978-1-4471-7293-2_81 · Cited by 2
Soluble guanylate cyclase stimulators and phosphodiesterase-5 inhibitors in therapy of some groups of pulmonary hypertension
Ivanov, K. I. (2018) · PULMONOLOGIYA · doi:10.18093/0869-0189-2017-27-6-803-810 · Cited by 2
The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension
Gu, Z., Zhang, Y.-J., Pan, M.-M., Zhang, C., Liu, X.-Y., Wei, A., & Su, Y.-J. (2018) · Medicine · doi:10.1097/md.0000000000010122 · Cited by 1
Pulmonary hypertension: An update of Dx and Tx guidelines
Singh, M. (2023) · The Journal of Family Practice · doi:10.12788/jfp.0561 · Cited by 1
Craniofacial Hypoplasia and the Difficult Airway
Huynh, K., Gritsenko, K., Breidenbach, K. A., Diaz, S., Sterling, F. D., Koushik, S. S., Viswanath, O., Borowski, B. T., Shaparin, N., & Lee, K. H. (2026) · Orthopedic Reviews · doi:10.52965/001c.157900 · Cited by 1
The Innovations in Pulmonary Hypertension Pathophysiology and Treatment: What are our Options!
Kalani, C., Garcia, I., Ocegueda-Pacheco, C., Varon, J., & Surani, S. (2019) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x15666190117133311 · Cited by 1
Advances in Management of Pulmonary Hypertension Associated with Systemic Sclerosis
Swisher, J. W., & Kailash, S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.86217 · Cited by 1
Emergency Medicine Curriculum Utilizing the Flipped Classroom Method: Pulmonary Emergencies
Branditz, L. D., King, A., Kaide, C. G., Mitzman, J. M., Ostro, B., Martín, D. E. A., Kman, N. E., Bahner, D. P., Werman, H. A., Thema, T., et al. (2019) · Journal of Education and Teaching in Emergency Medicine · doi:10.5070/m544045605 · Cited by 1

Authors: Taichman, D. B., Ornelas, J., Chung, L., Klinger, J. R., Lewis, S., Mandel, J., Palevsky, H. I., Rich, S., Sood, N., Rosenzweig, E. B., Trow, T. K., Yung, R., Elliott, C. G., & Badesch, D. B.
Affiliations: University of Pennsylvania (US)
American College of Chest Physicians (US)
VA Palo Alto Health Care System (US)
Brown University (US)
University of California San Diego (US)
University of Chicago (US)
The Ohio State University (US)
Columbia University Irving Medical Center (US)
Yale University (US)
Johns Hopkins University (US)
University of Utah (US)
University of Colorado Denver (US)
Corresponding author: Ornelas, Joe
ORCID: Taichman, Darren B.
Chung, Lorinda
Klinger, James R.
Lewis, Sandra
Mandel, Jess
Palevsky, Harold I.
Rich, Stuart
Sood, Namita
Rosenzweig, Erika B.
Elliott, C. Gregory
Venue: Chest
Publisher: Elsevier BV
Published: 2014-08
Volume: 146
Issue: 2
Pages: 449-475
ISSN: 0012-3692 (ISSN-L)
DOI: 10.1378/chest.14-0793
PMC: PMC4137591
OpenAlex: W2157947374
Cited by: 256
References: 104
Citations by year: 2026: 6 · 2025: 7 · 2024: 6 · 2023: 5 · 2022: 13 · 2021: 18 · 2020: 14 · 2019: 25 · 2018: 29 · 2017: 43 · 2016: 40 · 2015: 43 · 2014: 5
FWCI: 7.47
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: CHEST Journal (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords: pulmonary arterial hypertension, pharmacotherapy, adult patients, antihypertensive drugs, consensus statement, treatment guidelines, level of evidence
MeSH terms: Adult, Antihypertensive Agents, Delphi Technique, Humans, Hypertension, Pulmonary, Practice Guidelines as Topic, Consensus, Familial Primary Pulmonary Hypertension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks